Investigation of treatment volume versus circulating blood volume during Rheocarna treatment.
Ther Apher Dial
; 28(4): 505-510, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38453633
ABSTRACT
INTRODUCTION:
Rheocarna's therapeutic effect is associated with fibrinogen (Fib) and low-density lipoprotein cholesterol (LDL-C) adsorptive removal. This study aimed to retrospectively investigate the association between treatment volume (TV) and circulating blood volume (CBV) and the Fib removal rate (Fib-RR) and LDL-C-RR.METHODS:
CBV and TV/CBV, cut-off value (CO value), and area under the receiver operating characteristic (ROC) curve (AUC) were calculated. The Fib-RR and LDL-C-RR at the midterm and end of treatment were compared. The groups were further categorized into three groups with TV/CBV lower than or higher than the CO value at the midterm and end (midterm/end; Group L lower than/lower than CO; Group L/H lower than/higher than CO; Group H higher than/higher than CO), and the Fib-RR and LDL-RR of each group at the midterm and end were compared.RESULTS:
ROC analysis revealed a TV of 1.480 times the BV as CO value, which showed a maximum Youden index predicting a Fib-RR of 20% (AUC 0.828). Among the three groups, Group L and Group L/H demonstrated significantly higher Fib-RR and LDL-C-RR at the end of the study than in the midterm, while Group H exhibited no difference.CONCLUSION:
The results reveal that a treatment volume of 1.5 times the circulating blood volume is a sufficient solute removal capacity in the Rheocarna-enabled cases.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Volumen Sanguíneo
/
Fibrinógeno
/
LDL-Colesterol
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Ther Apher Dial
/
Therapeutic apheresis and dialysis
Asunto de la revista:
HEMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón